INZY

Inozyme Pharma

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 0

consensus rating "Buy"

EPS Beats Expectation

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About INZY

Inozyme Pharma, Inc.

A clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization

Industry

Biological Technology

Established Date

Invalid Date

Listing Date

07/24/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.inozyme.com

Security Type

Common stock

Office address

321 Summer Street, Suite 400, Boston, Massachusetts 02210

Business

Introduction

Inozyme Pharma, Inc., was established in September 2015 under the laws of the State of Delaware. The company is a rare disease biopharmaceutical company focused on developing novel therapies to treat abnormal mineralized diseases affecting blood vessels, soft tissues and bones. With a deep understanding of the biological pathways involved in mineralization, the company is committed to developing therapeutic agents to address the root causes of these debilitating diseases.

Company Financials

EPS

INZY has released its 2024 Q4 earnings. EPS was reported at -0.41, versus the expected -0.37, missing expectations. The chart below visualizes how INZY has performed over recent quarters, highlighting trends in earnings surprises.